Kutatási jelek – Signal Engine

• Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B‑cell lymphoma in the era of CAR‑T and novel immunotherapies — Diffuse large B-cell lymphoma
• Metabolic tumor volume and total lesion glycolysis for predicting prognosis in diffuse large B-cell lymphoma: a retrospective PET/CT study — Diffuse large B-cell lymphoma
• Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma — Diffuse large B-cell lymphoma
• Therapeutic outcomes of TP53-mutated diffuse large B cell lymphoma: A systematic review and meta-analysis — Diffuse large B-cell lymphoma
• Prognostic value of the CONUT score in newly diagnosed diffuse large B‑cell lymphoma — Diffuse large B-cell lymphoma
• Frontiers | Case Report: Discordant diffuse large B-cell lymphoma and splenic peripheral T-cell lymphoma revealed by persistent splenomegaly and cytopenia — Diffuse large B-cell lymphoma
• Optimal peritumoral regions and fusion strategies for prediction of the double-expressor subtype in diffuse large B-cell lymphoma: a multi-region radiomics study — Diffuse large B-cell lymphoma
• The revelation of immune cell interaction and the building of a prognostic model in diffuse large B-cell lymphoma under Hedgehog signaling abnormalities based on single-cell data — Diffuse large B-cell lymphoma
• Frontiers | Case Report: Diagnostic pitfall and biomarker-guided therapy in CD20-negative Epstein‑Barr virus-positive diffuse large B‑cell lymphoma — Diffuse large B-cell lymphoma
• Extranodal involvement defines distinct immune-molecular phenotypes and clinical outcomes in diffuse large b-cell lymphoma — Diffuse large B-cell lymphoma
• Current treatment algorithm: diffuse large B cell lymphoma — Diffuse large B-cell lymphoma
• Unveiling the epigenetic landscape: transforming renal cell carcinoma treatment — Renal cell carcinoma
• Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group — Renal cell carcinoma
• Association between antidepressant use and overall survival in metastatic renal cell carcinoma treated with first-line targeted therapy — Renal cell carcinoma
• YAP delactylation enhances therapy resistance in renal cell carcinoma — Renal cell carcinoma
• Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first‑line immunotherapy‑based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) — Renal cell carcinoma
• Evaluation of QTc interval prolongation in patients with advanced clear cell renal cell carcinoma treated with first line sunitinib — Renal cell carcinoma
• Baseline and three-month De Ritis ratio and gamma-glutamyltransferase as prognostic biomarkers in metastatic renal cell carcinoma treated with targeted therapy — Renal cell carcinoma
• Racial and ethnic disparities in the cause of death for clear cell renal cell carcinoma — Renal cell carcinoma
• Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape — NSCLC